D.C. Mun. Regs. tit. 22-A, § 6346
6314
6315
6316
6317
6318
6319
6320
6321
6322
6324
6325
6326
6327
6328
6329
6330
6331
6332
6333
6334
6335
6336
6337
6338
6339
6340
6341
6342
6343
6346
6246
6247
6248
6249
6250
6251
6252
6253
6254
6255
6256
6257
6258
6259
6260
6261
6262
6263
6264
6265
6266
6267
6268
6269
6270
6271
6272
6273
6274
6275
6276
6277
6278
6279
6280
6281
6282
6283
6284
6285
6286
6287
6288
6289
6290
6291
6292
6293
6294
6295
6296
6297
6298
6299
6300
6301
6302
6303
6304
6305
6306
6307
6308
6309
6310
6311
6312
6313
6314
6315
6316
6317
6318
6319
6320
6321
6322
6323
6324
6325
6326
6327
6328
6329
6330
6331
6332
6333
6334
6335
6336
6337
6338
6339
6340
6341
6342
6343
6344
6345
6346
6346.1 MSUD is the use of FDA-approved medications in accordance with the client's Plan of Care for the treatment of SUD, including OUD. OTPs shall not preclude clients who refuse SUD Counseling/Therapy from receiving MSUD. Providers shall administer MSUD in accordance with all governing Federal regulations.
6346.2 Clients receiving MSUD must meet diagnostic criteria for:
(a) Active moderate to severe SUD;
(b) Being in SUD remission; or
(c) Being at high risk for recurrence or overdose.
6346.3 Providers shall ensure that clients receiving MSUD understand and provide written or verbal informed consent and document the informed consent in the client's medical record.
6346.4 Providers may deliver MSUD in-office, through a mobile unit, or as a take-home regimen in accordance with all governing Federal regulations. Providers shall ensure that all MSUD administrations include the unit of medication and therapeutic guidance in accordance with § 6346.5 and all governing Federal regulations. For clients receiving a take-home regimen, therapeutic guidance shall include guidance related to storage and self-administration.
6346.5 Therapeutic guidance provided during MSUD shall include:
(a) Safeguarding medications;
(b) Possible side-effects and interaction with other medications;
(c) Impact of missing doses;
(d) Monitoring for withdrawal symptoms and other adverse reactions;
(e) Appearance of medication and method of ingestion; and
(f) For clients receiving a take-home regimen, therapeutic guidance shall include additional guidance related to storage and self-administration.
6346.6 The provision of MSUD shall be accompanied by SUD treatment services in accordance with the client's Plan of Care.
6346.7 Providers shall document MSUD services through medication log updates and
an encounter note for each visit, including therapeutic guidance.
6346.8 Qualified Practitioners of MSUD are:
(a) Physicians; and
(b) APRNs.
6346.9 The following may deliver MSUD under the direction of a Qualified Practitioner:
(a) PAs.
(b) RNs; or
(c) LPNs.
SOURCE: Final Rulemaking published at 62 DCR 12056 (September 4, 2015); as amended by Final Rulemaking published at 67 DCR 011585 (October 9, 2020); as amended by Final Rulemaking published at 72 DCR 008497 (August 1, 2025).